Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

Core Insights - Orion Corporation and Glykos Finland Oy have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs) [1] Group 1: Agreement Details - Under the extended agreement, Orion will gain access to Glykos' proprietary ADC technologies, allowing for the potential expansion into three additional programs beyond the initial three outlined in the previous agreement [2] - Orion will be responsible for target selection, research, development, and commercialization of up to three next-generation ADCs, focusing on solid tumors [2] - The financial terms for the new ADC projects remain consistent with the original agreement, including milestone payments and royalties for Glykos related to product sales [3] Group 2: Company Statements - Orion emphasizes the importance of this collaboration in leveraging advanced ADC technology to develop new treatment options for cancer patients, as stated by Professor Outi Vaarala, Executive Vice President at Orion [4] - Glykos highlights the potential of their ADC technology and the significance of Orion's expertise in cancer therapies for effective treatment development, as mentioned by CEO Juhani Saarinen [5] Group 3: Company Background - Orion is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing pharmaceuticals and active pharmaceutical ingredients, particularly in oncology and pain [6] - Glykos specializes in ADCs, aiming to revolutionize cancer treatment with proprietary technology that enhances efficacy, tolerability, and pharmacokinetics [7]